<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862276</url>
  </required_header>
  <id_info>
    <org_study_id>KHBO1206</org_study_id>
    <secondary_id>UMIN000010416</secondary_id>
    <nct_id>NCT01862276</nct_id>
  </id_info>
  <brief_title>Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Hepatobiliary Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansai Hepatobiliary Oncology Group</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the prognosis due to presence or absence of bile duct resection in
      intrahepatic cholangiocarcinoma that require hepatic lobectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bile duct resection in hepatic lobectomy due to cholangiocarcinoma, mass forming type,
      is still controversial.  We retrospectively evaluated the effect of bile duct resection in
      this surgery.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>3-year recurrence-free survival rate</measure>
    <time_frame>11 years (2000-2010)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of local recurrence at the hepatico-duodenal ligament</measure>
    <time_frame>11 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent hepatic lobectomy between 2000 and 2010 for intrahepatic
        cholangiocarcinoma, and did not undergo adjuvant chemotherapy will be included for
        analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases of major hepatectomy due to intrahepatic cholangiocarcinoma

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Nagano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka University, Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University, Graduate School of Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
